Montelukast-induced anxiety in two pediatric patients

Pharmacotherapy

Volumn 31, Issue 5, 2011, Pages

  Skillman, Katherine L ^a   Stumpf, Janice L ^b,c  

^a WISHARD HEALTH SERVICES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anxiety; Leukotriene receptor antagonist; Montelukast; Nervousness

Indexed keywords

CETIRIZINE; FLUTICASONE; MONTELUKAST; SALBUTAMOL;

ANGER; ANXIETY; ARTICLE; ASTHMA; BEDTIME DOSAGE; BEHAVIOR DISORDER; CASE REPORT; CHILD; COUGHING; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAY FEVER; HUMAN; MALE; NIGHTMARE; PRESCHOOL CHILD; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SLEEP WALKING; STOMACH PAIN; SYMPTOM; TREATMENT DURATION;

EID: 79955575016     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.5.524     Document Type: Article

References (27)

1. Merck & Co., Inc. Singulair (montelukast sodium) package insert. Whitehouse Station, NJ; May 2010.
2. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007;14:1966-77. (Pubitemid 47209107)
3. U.S. Food and Drug Administration. Early communication about an ongoing safety review of montelukast (Singulair), March 27, 2008. Available from http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/ DrugSafetyInformationforHeathcareProfessionals/ ucm070618.htm. Accessed November 18, 2010.
4. U.S. Food and Drug Administration. Followp-up to the March 27, 2008, communication about the ongoing safety review of montelukast (Singulair), January 13, 2009. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm079523.htm. Accessed November 18, 2010.
5. Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
6. Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
7. U.S. Food and Drug Administration. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR), June 12, 2009. Updated August 28, 2009. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/Dru gSafetyInformationforHeathcareProfessionals/ucm165489.htm. Accessed November 18, 2010.
8. Brunlöf G, Tukukino C, Wallerstedt SM. Individual case safety reports in children in commonly used drug groups - signal detection. BMC Clin Pharmacol 2008;8:1-5.
9. Medicines and Healthcare Products Regulatory Agency and Committee on Safety of Medicines. Leukotriene receptor antagonists: update on adverse reaction profiles. Curr Probl Pharmacovigilance 1999;25:14.
10. Biswas P, Wilton L, Pearce G, Freemantle S, Shakir S, Mann RD. Pharmacosurveillance and safety of the leukotriene receptor antagonist (LTRA), montelukast. Clin Exp All Rev 2001;1:300-4. (Pubitemid 33754905)
11. Wallerstedt SM, Brunlöf G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
12. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:568-79.
13. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients ages ≥ 6 years. Clin Exp All 2001;31:77-87. (Pubitemid 32158764)
14. U.S. Food and Drug Administration. Data on file. MedWatch adverse event reporting system. Freedom of information request. Silver Spring, MD; January 14, 2009.
15. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9.
16. Consumer Health Resource Group, LLC. Ask a patient: medicine ratings and health care opinions. Singulair. Available from http://www.askapatient.com/ viewrating.asp?drug= 20829&name=SINGULAIR&page=1. Accessed July 15, 2010.
17. Medications.com. Singulair side effects. Available from http://www.medications.com/se/singulair. Accessed July 15, 2010.
18. Twaites BR, Wilton LV, Shakir SAW. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. Drug Saf 2007;30:419-29. (Pubitemid 46740338)
19. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007;357:1841-54.
20. Brink C, Dahlen S, Drazen J, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003;55:195-227.
21. Knorr B, Larson P, Nguyen HH, et al. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999;39:786-93. (Pubitemid 30629436)
22. Knorr B, Nguyen HH, Kearns GL, et al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001;41:612-19. (Pubitemid 32493355)
23. Migoya E, Kearns GL, Hartford A, et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004;44:487-94. (Pubitemid 38509717)
24. Katon WJ, Richardson L, Lozano P, McCauley E. The relationship of asthma and anxiety disorders. Psychosom Med 2004;66:349-55. (Pubitemid 38668403)
25. GlaxoSmithKline. Ventolin HFA (albuterol sulfate) aerosol package insert. Research Triangle Park, NC; August 2009.
26. Pfizer Labs. Zyrtec (cetirizine hydrochloride) package insert. Smyrna, GA; May 2006.
27. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)